Systematic Review of Pharmacogenetic Warfarin Dosing by van Schie, Rianne M. F. et al.
LETTER TO THE EDITOR
Systematic Review of Pharmacogenetic Warfarin Dosing
Rianne M. F. van Schie, MSc
1, Andrea L. Jorgensen, MSc
2, Anthonius de Boer, MD, PhD
1,
Anke-Hilse Maitland-van der Zee, PharmD, PhD
1 and for the EU-PACT study group
1Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute of Pharmaceutical Sciences (UIPS), Utrecht University,
Utrecht, the Netherlands;
2Centre for Medical Statistics and Health Evaluation, University of Liverpool, Liverpool, UK.
To the Editor: —In the article
1 by Neudoerffer et al. the safety
and efficacy of genotype-guided dosing of warfarin was de-
scribed. The conclusion was that there is not sufficient evidence
tosupporttheuseofpharmacogeneticstoguidewarfarindosing
and that additional clinical trials are necessary. An overview of
these additional and ongoing clinical trials was given in Table 5.
At least five ongoing clinical trials were identified, to which we
would like to add a sixth randomized trial. Details of this study
design are expected to be published soon.
The EUropean Pharmacogenetics of AntiCoagulation Ther-
apy (EU-PACT) trial will investigate the added value of pre-
treatment genotyping for anticoagulation therapy with
warfarin, acenocoumarol and phenprocoumon. In February
2010 the inclusion of 985 patients using a coumarin derivate
in the EU-PACT trial will start. EU-PACT is funded by the
European Community's Seventh Framework Programme
(grant agreement number HEALTH-F2–2009–223062). The
trial will be performed at 13 centers in seven European
countries, which makes extrapolation of the results to other
(European) countries feasible. The primary outcome measure
is percentage time of the INR within the therapeutic range.
Secondary outcomes are, among others, major hemorrhage,
the cost-effectiveness of pretreatment genotyping, and the
clinical utility of the rapid genotyping instrument that we will
implement.
The EU-PACT trial will evaluate the cost-effectiveness of
genotype-guided dosing of three different coumarin derivatives.
Furthermore, we will investigate the utility of a rapid genotyping
instrument, which makes it possible to prescribe a personalized
dosetothepatientincludinghisgeneticinformationfromdayone.
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